Commonly used total PSA medical decision concentrations for prostate cancer screening range from 2.5 to 10.0 μg/L but the medical decision range for monitoring can span from the assay’s lower limit of quantitation to 20.0 μg/L or more (11). This evidence concerns the gene KLK3 and prostate cancer.